Cardiff Oncology Announces Leadership Changes Amidst Transition to Late-Stage Clinical Development

martes, 27 de enero de 2026, 4:04 pm ET1 min de lectura
CRDF--

Cardiff Oncology has appointed Mani Mohindru as interim CEO, replacing Mark Erlander and James Levine. Mohindru, a seasoned biotech executive, has been a member of the company's Board of Directors since 2021. The change in leadership is aimed at supporting Cardiff Oncology's growth and advancement towards late-stage clinical development.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios